Efficacy of subcutaneous <i>vs</i> intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
Arnaud Constantin, Dae‐Hyun Yoo(Hanyang University Seoul Hospital), Seungmin Kim(Celltrion (South Korea)), Hendrik Schulze‐Koops(LMU Klinikum), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Edward Keystone(University of Toronto), Dong‐Hyeon Kim(Celltrion (South Korea)), Taek Sang Kwon(Celltrion (South Korea)), Gahee Park(Celltrion (South Korea)), Florenzo Iannone(University of Bari Aldo Moro), Roberto Caporali(University of Milan), João Eurico Fonseca(University of Lisbon)
Cited by 6
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
|Arthritis & Rheumatism|2002|733